eCommons@AKU
Department of Medicine

Department of Medicine

February 2012

My patient has an elevated hs-CRP. What does this
mean? What should I do now?
Maria Khan
Aga Khan University

Emmon Raza
Aga Khan University

Ayeesha Kamran Kamal
Agha Khan University, ayeesha.kamal@aku.edu

Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Neurology Commons
Recommended Citation
Khan, M., Raza, E., Kamal, A. (2012). My patient has an elevated hs-CRP. What does this mean? What should I do now?. JPMA. The
Journal of the Pakistan Medical Association, 62(2), 182-183.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/370

Evidence Based Medicine
My Patient has an elevated hs-CRP. What does this mean? What should I do now?
Maria Khan,1 Emmon Raza,2 Ayeesha Kamran Kamal3
International Cerebrovascular Translational Clinical Research Training Program, Stroke Service,1 Medical College,2
Stroke Service and Vascular Fellowship Program,3 Aga Khan University Hospital, Karachi, Pakistan.

Why is this trial important?
Hyperlipidaemia is an established risk factor for
cardiovascular and cerebrovascular disease. A standard
investigation to assess a person's hyperlipidaemia is the lipid
profile. This measures total cholesterol, high density
lipoproteins (HDL), low density lipoproteins (LDL) and
triglycerides. LDL has been implicated most as the culprit
behind these vascular events. However, new research has
shown that a raised high sensitivity C - reactive protein (hsCRP), a biomarker for inflammation, is a predictor for systemic
vascular endothelial inflammation and future vascular event
independent of a person's LDL level.
Statins, the wonder drug for high LDL and cholesterol,
have been in use for vascular protection for long. They have an
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established benefit for cardioprotection and stroke risk
reduction in people with high cholesterol. However, if statins
offer any benefit in people with low to normal Cholesterol and
raised hs-CRP was not known.
The JUPITER trial was undertaken with the objective of
assessing the benefits of statins in reducing the risk of future
vascular events in asymptomatic patients with cholesterol
already in the desirable range but elevated hs-CRP.

Who were the participants?
A total of 17,802 individuals from 26 countries were
enrolled for the trial. There was representation of Caucasians,
Blacks and Hispanics from North and South America, Africa
and Europe.
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Men aged > 50 years and women aged > 60 years with
no vascular co-morbidities and LDL level <130 mg/dL and hsCRP level > 2.0 mg/dL were eligible.
The study population had a mean age of 66 years with
slight male preponderance. Study participants matched in terms
of their co-morbidity status.

What was the intervention?
JUPITER was a double-blind, placebo-controlled trial.
The study subjects were randomly allocated to two groups. The
intervention group was administered 20 mg Rosuvastatin daily.
The control group received a placebo pill. The two groups were
followed for a median duration of 1.9 years and their lipid levels
and hs-CRP were assessed both at baseline and yearly thereafter
for as long as they were part of the study. The primary end-point
of interest was fatal and non-fatal stroke.

What was the outcome?
At the end of the study period, the incidence rate for
stroke in the Rosuvastatin group was 0.18 compared with 0.34
in the placebo group (p=0.002) translating to a 48% risk
reduction. Although Rosuvastatin reduced the risk of ischemic
stroke compared to a placebo (p=0.004), it was similar to
placebo in preventing haemorrhagic stroke (0.44) and transient
ischaemic attack (p=0.79). No excess risk of haemorrhagic
strokes was observed with statin therapy.
The benefits of therapy extended beyond the high risk
group. People who were categorized as low risk based on body
mass index <25 kg/m2, without the metabolic syndrome, with a
Framingham risk score <10, with low levels of LDL-C (<100
mg/dL), with normal levels of HDL-C), and with normal
triglyceride levels (<150 mg/dL) also had similar benefits from
therapy.
Twelve months of daily 20 mg Rosuvastatin was able to
bring down the LDL and Cholesterol levels by 50% and the hsCRP levels by 37%. The greatest stroke risk reduction with
Rosuvastatin was seen in participants who achieved LDL <70
mg/dL and hs-CRP < 2 mg/L.
The adverse effect profile was similar in both groups
except a slightly high incidence of Diabetes in the Rosuvastatin
group (p=0.01).
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What were the conclusions?
The investigators concluded that use of prophylactic
cholesterol-lowering therapy is justified in people with normalrange LDL and cholesterol but raised hs-CRP. Daily use of
20mg Rosuvastatin was associated with a 39% relative
reduction in ischaemic stroke risk for each 1mmol/L reduction
in LDL level.
Other trials, namely, WOSCOPS, MEGA, AFCAPSTexCAPS; have proven the advantage of statin therapy on
stroke risk reduction in people with high LDL levels and
JUPITER proves it in people with desirable LDL and raised hsCRP levels.

What implications does this study have for the
Pakistani medical practitioners?
Daily Rosuvastatin promises reduction in the risk of
stroke by 48% in people with normal-range cholesterol who are
nonetheless at risk for vascular events due to elevated hs-CRP
levels. This is a new vascular intervention point to consider in
asymptomatic patients with LDL<130 but raised High
Sensitivity C reactive protein levels above 2.
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